New hope for HIV patients: shorter, stronger fungal infection treatment on trial
NCT ID NCT06525389
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two new ways to treat talaromycosis, a serious fungal infection in people with HIV. It compares a single high dose of a newer antifungal drug (liposomal amphotericin B) against two weeks of the standard drug, and also checks if adding another medicine (flucytosine) helps. The trial will include 428 adults with HIV and confirmed talaromycosis. The goal is to find a more effective and simpler treatment to reduce deaths and complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TALAROMYCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bach Mai Hospital
Hanoi, Vietnam
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Hospital for Tropical Diseases
Ho Chi Minh City, 7000, Vietnam
-
National Hospital for Tropical Diseases
Hanoi, Vietnam
-
Pham Ngoc Thach University of Medicine
Ho Chi Minh City, 7000, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.